Overview

Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High Signature

Status:
NOT_YET_RECRUITING

Trial end date:
2026-05-01

Target enrollment:

Participant gender:

Summary

This trial will study the effectiveness of ACT001 in adult patients whose Glioblastoma have recurred with a STAT3-high signature after standard-of-care treatment with at least radiation therapy.

Phase:

PHASE2

Details

Lead Sponsor:

National Neuroscience Institute

Treatments:

ACT001